LAVA Therapeutics (LVTX) Competitors $1.24 -0.01 (-0.80%) Closing price 04:00 PM EasternExtended Trading$1.18 -0.06 (-4.84%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. DERM, FATE, FDMT, PBYI, TARA, IKT, PRQR, TLSA, NKTX, and CHRSShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Journey Medical (DERM), Fate Therapeutics (FATE), 4D Molecular Therapeutics (FDMT), Puma Biotechnology (PBYI), Protara Therapeutics (TARA), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), Tiziana Life Sciences (TLSA), Nkarta (NKTX), and Coherus BioSciences (CHRS). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Journey Medical Fate Therapeutics 4D Molecular Therapeutics Puma Biotechnology Protara Therapeutics Inhibikase Therapeutics ProQR Therapeutics Tiziana Life Sciences Nkarta Coherus BioSciences LAVA Therapeutics (NASDAQ:LVTX) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Does the MarketBeat Community believe in LVTX or DERM? LAVA Therapeutics received 19 more outperform votes than Journey Medical when rated by MarketBeat users. However, 85.71% of users gave Journey Medical an outperform vote while only 65.79% of users gave LAVA Therapeutics an outperform vote. CompanyUnderperformOutperformLAVA TherapeuticsOutperform Votes2565.79% Underperform Votes1334.21% Journey MedicalOutperform Votes685.71% Underperform Votes114.29% Does the media refer more to LVTX or DERM? In the previous week, Journey Medical had 3 more articles in the media than LAVA Therapeutics. MarketBeat recorded 5 mentions for Journey Medical and 2 mentions for LAVA Therapeutics. LAVA Therapeutics' average media sentiment score of 1.43 beat Journey Medical's score of 0.56 indicating that LAVA Therapeutics is being referred to more favorably in the media. Company Overall Sentiment LAVA Therapeutics Positive Journey Medical Positive Do insiders and institutionals believe in LVTX or DERM? 7.3% of Journey Medical shares are held by institutional investors. 0.8% of LAVA Therapeutics shares are held by insiders. Comparatively, 13.2% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, LVTX or DERM? LAVA Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Is LVTX or DERM more profitable? LAVA Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. LAVA Therapeutics' return on equity of -62.22% beat Journey Medical's return on equity.Company Net Margins Return on Equity Return on Assets LAVA TherapeuticsN/A -62.22% -29.37% Journey Medical -31.74%-132.10%-26.90% Which has higher valuation and earnings, LVTX or DERM? Journey Medical has higher revenue and earnings than LAVA Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLAVA Therapeutics$11.98M2.72-$41.97M-$0.93-1.33Journey Medical$56.13M2.83-$3.85M-$0.74-9.30 Do analysts rate LVTX or DERM? LAVA Therapeutics presently has a consensus target price of $3.17, suggesting a potential upside of 155.38%. Journey Medical has a consensus target price of $9.88, suggesting a potential upside of 43.53%. Given LAVA Therapeutics' higher probable upside, research analysts plainly believe LAVA Therapeutics is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryJourney Medical beats LAVA Therapeutics on 13 of the 19 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.62M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.207.3222.5118.54Price / Sales2.72241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book0.646.486.734.25Net Income-$41.97M$143.41M$3.22B$248.18M7 Day Performance-10.14%2.30%1.58%1.25%1 Month Performance-0.80%7.14%4.05%3.76%1 Year Performance-58.25%-2.61%15.75%5.28% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics2.3448 of 5 stars$1.24-0.8%$3.17+155.4%-56.7%$32.62M$11.98M-1.2060Short Interest ↓Positive NewsDERMJourney Medical2.6531 of 5 stars$6.33+1.3%$9.88+56.0%+101.1%$146.25M$56.13M-6.7390Short Interest ↑News CoverageFATEFate Therapeutics3.7454 of 5 stars$1.25+12.6%$5.43+334.3%-67.6%$143.26M$13.63M-0.76550Upcoming EarningsHigh Trading VolumeFDMT4D Molecular Therapeutics2.6219 of 5 stars$3.08+0.7%$26.71+767.3%-85.9%$142.61M$37,000.00-1.08120Upcoming EarningsNews CoveragePositive NewsPBYIPuma Biotechnology3.818 of 5 stars$2.86flat$7.00+144.8%-37.3%$141.89M$230.47M5.96200Upcoming EarningsAnalyst RevisionNews CoverageTARAProtara Therapeutics2.2488 of 5 stars$3.85-1.3%$20.40+429.9%+17.4%$141.55MN/A-1.3730Analyst ForecastNews CoverageGap DownIKTInhibikase Therapeutics1.5483 of 5 stars$1.89-0.5%$6.50+243.9%+53.7%$140.51M$260,000.00-0.716News CoveragePositive NewsPRQRProQR Therapeutics2.9085 of 5 stars$1.32+15.8%$9.50+619.7%-14.4%$138.88M$18.91M-4.13180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTLSATiziana Life Sciences0.4707 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News CoverageNKTXNkarta2.8394 of 5 stars$1.85+2.2%$14.86+703.1%-68.3%$131.27MN/A-0.98140Upcoming EarningsPositive NewsCHRSCoherus BioSciences3.5265 of 5 stars$1.06-5.4%$5.38+407.1%-47.4%$129.81M$266.96M-13.25330Upcoming EarningsAnalyst ForecastNews Coverage Related Companies and Tools Related Companies Journey Medical Alternatives Fate Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Puma Biotechnology Alternatives Protara Therapeutics Alternatives Inhibikase Therapeutics Alternatives ProQR Therapeutics Alternatives Tiziana Life Sciences Alternatives Nkarta Alternatives Coherus BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LVTX Stock Free LVTX Stock Alerts